Expert Interview
Expectations for Roche's (RHHBY) Phase 3 Aphinity Data Release Evaluating Perjeta in Adjuvant Treatment of HER2-Positive Breast Cancer. Market Potential and Chances of Approval will be Discussed
Ticker(s): RHHBYAn oncologist with significant experience treating HER2-Positive breast cancer. He or she will be familiar with the data surrounding Perjeta, Herceptin, and other treatments in the area.
Please describe your background and experience treating patients with HER2-positive breast cancer. How many patients do you see and what is your typical path of treatment? How does this differ for patients who have received another medication in the past?
Added By: pjloriaHow effective and safe are current treatments? How do the efficacy and safety of these treatments compare to Perjeta?
Added By: pjloriaHerceptin is currently used as a monotherapy and in combination with chemo and several other treatments including perjeta. Can you describe the safety and efficacy of each of these treatment options? What medications do you think are best for first-line treatment and for adjuvant treatment?
Added By: pjloriaWhat are important data points to look for in the trial besides long term survival rates? What data points will ultimately decide if more doctors use perjeta as an adjuvant treatment to Herceptin?
Added By: pjloriaHow differentiated is the mechanism of action for perjeta versus herceptin and other currently approved treatments?
Added By: pjloriaWhat do you see as perjeta's role in treatment of HER2-positive breast cancer over the next few years?
Added By: pjloriaAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
- Roche (RHHBY) Phase 3 APHINITY Results Expected in Q1 2017 Evaluating Perjeta in Adjuvant Breast Cancer RHHBY Occurred On: Mar 02, 2017
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
